prv-015
mAbexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2002 (NCT00433875)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-15INHIBITOR
IL15 inhibitor
Neutralizes IL-15 biologic activity.
CD38 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSEJ48MR05C3 ↗
- ChEMBLCHEMBL2109468 ↗
- ChEMBLCHEMBL2109467 ↗
Also known as
- amg 714
- amg-714
- humax-il15
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04424927 | Phase 2 | Aug 24, 2020 | Provention Bio, Inc. |
| NCT04338581 | Phase 2 | Jul 31, 2020 | Amgen, National Institute of Allergy and Infectious Diseases (NIAID), Yale University |
| NCT02637141 | Phase 2 | Mar 1, 2016 | Celimmune, University of Tampere |
| NCT02633020 | Phase 2 | Mar 1, 2016 | Celimmune, Free University of Amsterdam |
| NCT00443326 | Phase 2 | Mar 1, 2007 | Amgen |
| NCT00433875 | Phase 2 | Dec 1, 2002 | Amgen |
| NCT03439475 | N/A | — | Amgen |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 4 | 3 | 2 | 2002 |
| Celimmune | For profit | 2 | 2 | 1 | 2016 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2020 |
| Provention Bio, Inc. | For profit | 1 | 1 | 1 | 2020 |
| University of Tampere | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1